RepliCel Life Sciences Ret. em ativos
Qual é o Ret. em ativos de RepliCel Life Sciences?
O Ret. em ativos de RepliCel Life Sciences, Inc. é -52.42%
Qual é a definição de Ret. em ativos?
Retorno sobre os ativos indica como os ativos de uma empresa são lucrativos na geração de receita. É calculado dividindo-se o lucro líquido pelo total de ativos médios.
The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.
Ret. em ativos de empresas na Setor Health Care em TSXV em comparação com RepliCel Life Sciences
O que RepliCel Life Sciences faz?
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Empresas com ret. em ativos semelhantes a RepliCel Life Sciences
- Cardiff Oncology tem Ret. em ativos de -52.69%
- Better Plant Sciences tem Ret. em ativos de -52.61%
- Zenith Minerals tem Ret. em ativos de -52.56%
- Midatech Pharma Plc tem Ret. em ativos de -52.50%
- Mithra Pharmaceuticals SA tem Ret. em ativos de -52.47%
- Octopus Robots SAD tem Ret. em ativos de -52.45%
- RepliCel Life Sciences tem Ret. em ativos de -52.42%
- Eat Beyond Global tem Ret. em ativos de -52.36%
- Passage Bio Inc tem Ret. em ativos de -52.29%
- AbraPlata Resource tem Ret. em ativos de -52.27%
- GeNeuro SA (Switzerland) tem Ret. em ativos de -52.27%
- InspireMD Inc tem Ret. em ativos de -52.26%
- Amani Gold tem Ret. em ativos de -52.25%